STUDresearch · Non-peptide
AC-262
Also known as
AC262 · AC-262536
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral
Performance / endurance
Systemic SARM research chem.
What people say
AC-262 is an oral SARM discussed as a milder recomp or strength option than RAD/LGD. That reputation comes from sparse, mixed reports—not established human benefits or safety.
Doses people talk about
Reported labels are unverified, and the milder-SARM reputation does not establish safety.
How it may feel
Some describe energy, focus and modest strength or fullness; others report anxiety, bloating or little worthwhile change. Testosterone or Cardarine co-use complicates several accounts.
Reported oral band~10–30 mg/day oral
Forum/vendor templates include ~10–20 mg/day as a frequently described lower starting range; these are discussion figures, not a validated starting dose.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Early accountsMental lift or anxiety
- Continued useA lackluster 4-week run is also reported
- After one doseNo consistent duration reported
Cycles people discuss
Reported blocks include 4–8 weeks and the separate 6–8-week chart pattern, followed by weeks off. PCT and suppression are debated; no universal calendar is validated.
Timing
Morning use appears in logs, while side effects, training and sleep shape timing choices. Daily or split schedules are not proof of a human half-life.
Stacks
Testosterone and Cardarine appear in individual reports; older notes compare it with Ostarine/RAD. Solo accounts are easier to interpret than multi-agent stacks.
Watch for
Suppression / lipids: Assume class risks without clean long-term data.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No measured human half-life established by the sources checked.
The discovery abstract covers cell assays and castrated rats. Daily community schedules do not measure human clearance.
Bounded to the reviewed abstract and logs, not a claim that every possible unpublished PK dataset is absent.
- AC-262536 pharmacological characterization (Piu et al., 2008) (opens in a new tab)Abstract: functional AR assay and 2-week study in castrated male rats. Complete abstract retrieved through Europe PMC EXT_ID:18164613 after inconsistent PubMed rendering.Abstract-only review; cell and rat pharmacology, not a human concentration-time or recreational safety study. It supplies no human elimination half-life.
- AC-262 Experience — early mood/energy report and later updates (opens in a new tab)May 6, 2023 opening post, paragraphs 1–3 (rendered lines 19–21); author updates at lines 80–83, 122–138.Deleted author name, but post and cited updates readable. Concurrent weekly testosterone and subsequent supplement use; no tested product identity, controlled comparison or single-dose offset measurement.
Felt duration people report
An after-dose effect window is not established; reports describe days or weeks of ongoing use.
Early mental lift, anxiety and a lackluster 4-week run all occur in the checked accounts. Continued-use observations are not duration after one dose.
Unverified products, co-use and training changes; no dependable onset-to-offset measurement or consensus.
- AC-262 Experience — early mood/energy report and later updates (opens in a new tab)May 6, 2023 opening post, paragraphs 1–3 (rendered lines 19–21); author updates at lines 80–83, 122–138.Deleted author name, but post and cited updates readable. Concurrent weekly testosterone and subsequent supplement use; no tested product identity, controlled comparison or single-dose offset measurement.
- AC 262 — my findings and one interesting thought (opens in a new tab)mdmanifest, July 19, 2022 opening post, paragraphs 1–6 (rendered lines 19–24): morning use over 30 days, regained muscle but anxiety/stress.One unverified account after restarting training following a long break; previous PED use and anxiety susceptibility confound outcomes. Proposed future training-day use is not an observed result.
- My experience with AC-262 (Accadrine) — lackluster 4-week report (opens in a new tab)Jester90210, June 16, 2023, post #1 (rendered lines 85–90).Cardarine co-use, self-described product authenticity, no independent testing. Commercially linked forum/replies; comparison with a later OTR-AC stack is uncontrolled.
What people say
- Recomp lore: Sparse anecdotes vs RAD/LGD. anecdote
- Body-comp talk: AC-262 is discussed for recomp, strength continuity, or soft-tissue recovery depending on class. forum
- Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
- Suppression / lipid chatter: Hormonal agents pull bloodwork and PCT conversations even when marketed “mild.” forum
- Cycle thinking: Fixed on/off blocks dominate over indefinite daily use. forum
Doses people talk about
- Common oral research-chem band: roughly ~10–30 mg/day oral in forum/vendor templates; many start ~10–20 mg/day. forum
- Cycle talk: often ~6–8 weeks on with PCT chatter if stacked/suppressive. forum
- vs bigger SARMs: usually framed milder than RAD-140/LGD-4033 in mg charts — still hormonal risk. forum
- Framing: AC-262536 research SARM — thin human data; bodybuilding research-chem charts only. forum
How it may feel
- Days 1–7: Older generic notes describe injection-site reactions or oral GI/mood shifts before benefits; that is not proof of an injectable AC-262 route. In a newly checked oral-use thread, one person on testosterone reported early energy and mood lift; another morning-use account described anxiety instead of useful energy. forum
- Weeks 4–8: Typical experimental cycle talk when discussed. forum
- Day 1 and later checks: Route, sting and GI logistics in the older generic note are not a reliable AC-262 day-1 experience. Reports range from an early mental lift to no worthwhile strength change; one 4-week Cardarine-stacked run described bloating and lackluster results. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- Short cycles: Common when tried. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Unclear public human PK: Dosing-frequency lore is copied from other SARMs. The checked AC-262536 discovery abstract reports cell and rat pharmacology, not a measured human elimination half-life; oral community logs do not establish one. forum
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Published-PK distinction: Relevant human concentration-time data would outrank forum half-life memes. The reviewed AC-262536 discovery abstract is preclinical; this check does not supply a human PK estimate or validate a dosing interval. trial
More on what it is
- What it is: SARM research chem (AC-262536) with limited public human data relative to bigger names. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for AC-262, not proof it works for you. forum
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Rarely first-line: More experimental than Ostarine/RAD in older comparison talk. Checked accounts include testosterone co-use and a separate Cardarine stack, so their outcomes cannot be isolated to AC-262. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Suppression / lipids: Assume class risks without clean long-term data. forum
- General caution: Research chemical and compounded sources vary; adverse events may be under-reported. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Unapproved-drug status: SARMs are not FDA-approved for human use and are not legal dietary-supplement ingredients. This card maps forum talk only — not a sourcing guide, not a safety claim, and not a promise of results. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.